Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s - Wikidata - wikimedia - TriplyDB

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

http://www.wikidata.org/entity/Q36676379

about

Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.Changes in weight and weight distribution across the lifespan among HIV-infected and -uninfected men and women.Disease drivers of aging.Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.Metabolic Complications among Korean Patients with HIV Infection: The Korea HIV/AIDS Cohort Study.Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection.Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.Geriatric syndromes: new frontiers in HIV and sarcopenia.Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.Antiretroviral initiation is associated with increased skeletal muscle area and fat content.Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.Long-term body composition changes in antiretroviral-treated HIV-infected individuals.Improved adipose tissue function with initiation of protease inhibitor-only ART.Metabolic health across the body mass index spectrum in HIV-Infected and HIV-Uninfected Men.Differential relationships of hepatic and epicardial fat to body composition in HIV Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation.Endocrinological aspects of HIV infection.The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy.Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.Abdominal fat depots, insulin resistance, and incident diabetes mellitus in women with and without HIV infection Cardiac Steatosis in HIV-A Marker or Mediator of Disease?Insulin Resistance in HIV-Patients: Causes and Consequences Weight Gain: A Possible Side Effect of All Antiretrovirals

P2860

Q36654972-BD397AC1-CFB4-48FE-9BAB-50F1ECDDBDE0 Q37305570-06EB3A0C-89AC-4C4A-A354-F2BFAC02B0D3 Q37433073-AB63A158-E952-4D6F-8636-E9075E720DC1 Q37730342-A9DA62A8-35B6-4A23-86F2-FA7969DF6804 Q38376511-8A2920AC-3E8F-4F41-801E-56DAF9178E8C Q38700560-D14B76EB-F768-4948-B6BD-EB46038A184B Q38741518-0F19FFCC-D305-40A2-A006-035C6229BCEE Q38931905-B3653640-FB84-456B-98B1-B8E0E81F1A43 Q38936060-3CA752EF-0597-4B53-9857-AE75951357E5 Q38946641-3815066D-DDE3-42A5-A9F8-A610EA281CEB Q39283725-C66E87CE-6AEA-4A65-BB0C-DE0A3799474E Q39414284-80E3B355-82F6-4B7C-BC97-67935FFAB21E Q40181922-01996202-AF5F-4551-9623-F46737D27D16 Q40253823-BF7D9AE9-CA7A-407B-A74C-9CD221A97103 Q40529399-9C5540E7-DA97-4D46-876E-D4E55491AFAC Q40578427-05CF0822-0D8F-4764-A7D1-D6FA7FD0455D Q41934612-E047A66B-C615-40EE-A05A-912816D15ACD Q42378087-CA9CBB99-C5EC-4188-B995-EA4DB9F2B0BF Q47159869-6A22E86C-CCE9-483B-B81A-57415FCB19E1 Q47219853-F0890A2B-03B7-45F1-B227-61B58694C74C Q47891372-8233F675-5954-4E06-B99B-66434CF33256 Q52613761-B2CB01BE-9B04-46B6-9416-1FA847408C8B Q53691000-7761647A-F602-47C9-A19C-E01886D23A2B Q57173878-9C2AEB4C-13DA-4C5A-8655-EEFAD31DACC3 Q58572777-BA07AD79-7B29-447D-A83A-E037CFB9B5D2 Q58763014-55F2179C-56FD-4613-90DA-37A595A42556 Q58812046-CBB53296-7926-46A6-9519-CAF468244845

P2860

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

http://www.wikidata.org/entity/Q36676379

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@ast

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@en

type

label

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@ast

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@en

prefLabel

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@ast

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@en

P1433

Q36676379-A8E5ED71-22DF-4054-86DC-15BAB85582FB

P1476

Q36676379-23E54181-22F8-4783-9905-38D983979AA3

P2093

Q36676379-155F47BC-FE7D-4621-914A-92AA648BB89F

Q36676379-1B92AFBF-07D1-4515-9027-462B4180D08B

Q36676379-206E609A-FAE5-4FCC-A18F-59D6861DAEFE

Q36676379-56101326-1303-4C8E-ACC3-58E61DE4A518

Q36676379-5F5B80E0-88D2-438D-9AB0-4508DABCFD5F

Q36676379-61F74141-8CE4-41EF-8AB2-0048536572AF

Q36676379-76B9BA81-978A-4AE1-B113-C7B37931333F

Q36676379-F5E407B6-1FF8-4115-B75C-AA48231B5F30

P2860

Q36676379-124C0BB0-F3FC-4DAA-9CFC-D61C6C89E109

Q36676379-1298BC22-8AD6-47D8-BAEC-9E0D6CB42954

Q36676379-15AAFCD0-88B1-4A49-BD0E-3448310AC6C8

Q36676379-227C36B9-40FB-48A9-A840-F0C5AA3EC7CA

Q36676379-254F2E61-0F79-42BB-9F63-75584A207131

Q36676379-2E9DC8FE-0486-4EBF-97FE-9B4F57C12A7C

Q36676379-3DAF7269-B0BB-43A4-9D63-54269C9C2CCF

Q36676379-4ABBED5B-9F5A-4C62-8059-AF189FED84EC

Q36676379-57A4A11C-2D90-44D7-B805-5D43817CE54E

Q36676379-5F337F1E-C564-4B94-BD73-633E4A6D8A44

P304

Q36676379-EDF74A17-8995-4C50-9A9E-177D4FC84C48

P31

Q36676379-E68C85CB-2F0F-4859-9222-62DCB38E352F

P356

Q36676379-D9568E10-DADA-4928-AED0-81285F8B4E52

P407

Q36676379-5B5C05AD-3B09-4D43-8AD6-6A0072D1241A

P433

Q36676379-C9D36A3F-46D2-4720-85EE-1D420858A2C8

P478

Q36676379-14EBF73A-52CC-4F86-9F94-7FBF900B8497

P50

Q36676379-5225069C-7758-43CD-8811-86A276490DCB

Q36676379-96E8893B-93B2-49EF-A6E7-2A149E5D956D

P577

Q36676379-6430E72F-ECEC-489F-8A88-6203CEA3C62D

P698

Q36676379-D21AC82B-BE55-4B4B-9EC6-881383776827

P932

Q36676379-5F92CAA1-5551-4048-8932-974350411A38

P356

P1433

Clinical Infectious Diseases

P1476

Body Composition Changes After ...... otease Inhibitors: ACTG A5260s

@en

P2093

Carlee Moser

http://www.w3.org/2001/XMLSchema#string

Grace A McComsey

http://www.w3.org/2001/XMLSchema#string

Heather J Ribaudo

http://www.w3.org/2001/XMLSchema#string

Jennifer Rothenberg

http://www.w3.org/2001/XMLSchema#string

Judith Currier

http://www.w3.org/2001/XMLSchema#string

Michael P Dubé

http://www.w3.org/2001/XMLSchema#string

Pawel Paczuski

http://www.w3.org/2001/XMLSchema#string

Todd T Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection

Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study.

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.

Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.

Adipose-tissue and intestinal inflammation - visceral obesity and creeping fat

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.

Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda.

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

P304

853-862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIW017

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Theodoros Kelesidis

P577

2016-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26797215

http://www.w3.org/2001/XMLSchema#string

P932

4787610

http://www.w3.org/2001/XMLSchema#string